Black Diamond Therapeutics (BDTX) EBIT (2018 - 2021)
Historic EBIT for Black Diamond Therapeutics (BDTX) over the last 4 years, with Q4 2021 value amounting to -$26.1 million.
- Black Diamond Therapeutics' EBIT fell 1249.62% to -$26.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$119.3 million, marking a year-over-year decrease of 7154.23%. This contributed to the annual value of -$126.9 million for FY2021, which is 8236.6% down from last year.
- According to the latest figures from Q4 2021, Black Diamond Therapeutics' EBIT is -$26.1 million, which was down 1249.62% from -$35.4 million recorded in Q3 2021.
- In the past 5 years, Black Diamond Therapeutics' EBIT ranged from a high of -$3.0 million in Q4 2018 and a low of -$35.4 million during Q3 2021
- Over the past 4 years, Black Diamond Therapeutics' median EBIT value was -$14.0 million (recorded in 2020), while the average stood at -$16.5 million.
- As far as peak fluctuations go, Black Diamond Therapeutics' EBIT tumbled by 23959.29% in 2019, and later tumbled by 1249.62% in 2021.
- Over the past 4 years, Black Diamond Therapeutics' EBIT (Quarter) stood at -$3.0 million in 2018, then plummeted by 239.59% to -$10.3 million in 2019, then plummeted by 124.12% to -$23.2 million in 2020, then decreased by 12.5% to -$26.1 million in 2021.
- Its EBIT stands at -$26.1 million for Q4 2021, versus -$35.4 million for Q3 2021 and -$34.7 million for Q2 2021.